AbbVie has teamed up with Frontier Medicines to develop molecules against hard-to-drug targets. The collaborators will use Frontier’s technology for uncovering hidden binding pockets to develop protein degraders and small molecules against oncology and immunology targets.

A phase 3 trial of Ovid Therapeutics’ OV101 in Angelman syndrome has missed its primary endpoint, sending the biotech’s stock down 50%. Ovid has paused most other elements of its OV101 Angelman work in response to the setback and turned its focus to its next most advanced asset, OV935.

Zai Lab is looking to boost its cancer credentials and pipeline with the appointment of Roche oncology vet Alan Sandler, M.D.

Amgen has teamed up with cloud-based trial solutions firm Reify Health to help boost patients into its drug studies.

Janssen is tapping little-known and privately held Hemera Biosciences for a new gene therapy aimed at reversing a severe disease.

Noema Pharma has raised CHF54 million ($60 million) to advance clinical-stage neurological disease drugs it picked up from Roche. The series A gives ex-Roche Vice President George Garibaldi, M.D., a chance to realize the potential of assets that fell by the wayside at the Swiss pharma after posting lackluster data.

In the summer, Arena Pharmaceuticals hired Chris Cabell, M.D., as its chief medical officer, senior vice president and head of R&D, but now he’s out the door.

CAMBRIDGE, United Kingdom — Biofidelity Ltd, the cancer diagnostics company, today announced the opening of its new headquarters as it continues its significant recruitment ahead of commercialization of its first products. The Company has expanded into more than 500 square meters of office and laboratory space on Cambridge Science Park, one of Europe’s leading technology hubs and home to more than 130 businesses.

A host of top-suite venture capitalist firms has helped put together a meaty series A for an immuno-oncology biotech 2.0.

There is a host of treatments for people with asthma, from inhaled and oral corticosteroids to newer injected biologics. But these drugs don’t work for everyone, because different factors cause asthma in different people. Kinaset aims to close the treatment gap with a pan-JAK inhibitor designed to help patients regardless of what’s causing their disease.